AKUMS
DRUGS & PHARMACEUTICALS LTD.
Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, (Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000
CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Ref: Akums/Exchange/2025-26/79

February 13, 2026

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E),Mumbai – 400 051

Symbol: AKUMS

To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Scrip Code: 544222

Sub: **Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation**

Respected Sir/Madam,

In compliance of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of investor presentation is enclosed herewith.

This is for your kind information and record.

Thanking You

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Digitally signed by Dharamvir Malik
Date: 2026.02.13 17:24:36 +05'30'

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: as above

Registered Office
304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).
+91-11-47511000
+91-11-27023256

Q3 and 9M FY 25-26 Earnings Presentation

February 2026

Disclaimer

Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Akums Drugs and Pharmaceuticals Limited.

All information contained in this presentation has been prepared solely by Akums Drugs and Pharmaceuticals Limited. Akums Drugs and Pharmaceuticals Limited does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.

Managing Directors' **Message**

Dear Investors

We are pleased to declare the results for Q3FY26 as well as 9MFY26. Q3 FY26 was a strong quarter for Akums. Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of more than 16% driven by strong volumes. The international branded formulation business saw significant improvement led by demand recovery across key markets.

The quarter also saw benefits of operating leverage playing out in the CDMO business with improved capacity utilization as well as steady ramp up of newer facilities. While API pricing stayed under pressure, stabilization in select molecules and disciplined cost management has helped mitigate impact on the CDMO margins. We continue to work towards reducing losses in the trade generics and API segment by way of portfolio rationalization and tighter control over overheads.

Our European CDMO project is progressing as per our stated plans. We successfully advanced regulatory and execution milestones following the receipt of the EUGMP certification for our oral liquids' facility and are on track to start supplies in FY 28. Plant 1 also received renewal of EUGMP certification, showcasing our continued commitment towards global quality manufacturing. Supply of finished oral formulations from Plant 1 to Europe had already commenced this fiscal. The Zambia project also remains on track with commercial supplies from the Indian plants expected in H1 of FY27. These developments further showcase our progress towards establishing Akums as a global pharmaceutical company.

During Q3 FY26, the API business remained under pressure, with pricing softness persisting across key molecules; however, the pace of decline moderated, and ongoing portfolio rationalization and cost optimization initiatives helped contain losses and improve sequential performance.

While we continue to operate in a volatile business environment marked by disruptions, we, as Akums, remain focused on our long-term growth drivers that include innovation, operational efficiency, cost controls and strategic partnerships. We reiterate our commitment to creating long term value for our shareholders.

Thank you for your continued trust and support.

- **Sanjeev Jain & Sandeep Jain**

Two Decades' Legacy of **Expertise, Experience & Trust**

2004

Incorporated in April 2004

Set up of **first plant for oral solid dosage form** in Haridwar.

2005-09

Established dedicated manufacturing site for **Oral Liquid Dosage & Sterile products.**

Established a **nutraceutical** facility

2010-13

Dedicated facilities for **Hormones, Cosmetics and Dermatology.**

Launched **Akumentis to venture into branded formulations.**

Started dedicated plant for **β-lactam anti-infectives** and steroids

2014-18

Expanded into **Asian markets.**

Established R&D lab in Mumbai **to venture into regulated market.**

Received **US-NSF Certification for Maxcure Nutravedics** facility

2019-21

Acquired Parabolic Drugs to **venture into API**

2022-26

Plant 1 ,2 & 3 received EU-GMP accreditation

Listed on NSE and BSE

Started **new injectable** facility

ANVISA certified for Plant 3

2004 ← **Build** → 2010 ← **Strengthen** → 2021 ← **Accelerate** → 2025

Technologically Advanced Manufacturing Capabilities

Location	Haridwar	Haridwar	Haridwar	Haridwar	Haridwar	Haridwar	Haridwar	Haridwar	Kotdwar	Baddi	Haridwar
Year	2004	2007	2007	2010	2010	2010	2014	2014	2021	2023	2024
Annual Capacity (Cr units)	649	15	39	244	6	252	2.603	732	17	368	36
Capability	General	General	General	Hormonal	Cosmetics	Ayurvedic / Nutraceuticals	General	β-lactams and steroids	Penem anti-infective	General	General
Dosage Forms	1	2	3	1 3 4	4	1 2	1 2 3 4	1 2 3 4	1 2 3	1 2	3

1 Oral Solid | 2 Oral Liquid | 3 Injectable / Sterile | 4 External / Topical

Key Accreditations*

- European Union GMP
- FDA (Food and Drug Administration Philippines)
- NSF International
- Bộ Y Tế (Ministry of Health)
- ISO 9001:2015 Certified Company
- EFDA (Ethiopian Food & Drug Authority)
- WHO GMP Certified
- NAFDAC
- Uganda National Drug Authority
- ANVISA

*Received by some or all facilities;

R&D Focus

Illustrative

Differentiated Dosage Forms


Tablet In Tablet


Bi-layered, Sustained Release Tablet in Tablet


Inlay Tablet


Multiple Tablets in Capsule


Pre-filled syringes


Lyophilized Vials


Smart Tablets


Gummies


Mouth Melting Powders in Sachet


Tri Layered Tablet

Innovative In-house Technologies

FAST ABSOL Technology	with solphilic technology	SAFTALONG™ Technology	DO.WEL®	Spornam™ TECHNOLOGY	With biophilic™ Technology	sportine® technology	Emulsol™ TECHNOLOGY
Mizet™ Technology	With nano Technology	EXCEDERM™ Technology	Ultramax TECHNOLOGY	EntroSeal Technology	UHVM TECHNOLOGY	Xanlong Technology	PRiBSYS TECHNOLOGY
Aquaject™ TECHNOLOGY	with e-SOl™ Technology	evt Technology	S-TAB TECHNOLOGY	Kurafast™ Technology	DUOKLIK™ TECHNOLOGY	AQUAderm Technology	SMPR TECHNOLOGY

(1) As of 31st March 2025

Key drivers as well as their trends during Q3FY26

Key drivers and their impact on Akums' performance

Strong volume growth, despite muted volumes in the IPM	API prices continue to remain soft though initial signs of stabilization	Operating leverage and ramp up of new facilities	Strong performance in branded exports
Akums' witnessed double digit volume growth even though IPM volumes grew at 1.2%*	API prices continued their downward trajectory though some stability witnessed for some molecules.	Overall capacity utilization improved to 47% driven by strong volume growth. New facilities ramping up steadily.	Exports more than doubled QoQ with healthy growth across focus countries

* Source: Awacs

Q3 FY 26

Financial Performance Highlights

Q3FY26 Performance Highlights

Consolidated Performance*

Total Income	EBITDA	PAT
1,194 cr	181 cr	68 cr
	15.2%	5.7%
(+16.5% YoY)	(+33.3% YoY)	(+2.1% YoY)

Operating Performance#

Revenue	EBITDA	PAT
1,160 cr	147 cr	86 cr
	12.7%	7.2%
(+14.8% YoY)	(+21.0% YoY)	(+29.5% YoY)

Segment Break-up

Business Vertical	Share in Q3 FY26 revenue
CDMO	**79.0%**
Domestic Branded Formulation	**9.9%**
API	**4.7%**
International Branded Formulation	**4.3%**
Trade Generics	**2.1%**

*Including other Income; #Excluding the one time impact of New Labour codes

9MFY26 Performance Highlights

Consolidated Performance*

Total Income	Adj. EBITDA	Adj PAT
3,295 cr	464 cr 14.1%	175 cr 5.3%
(+6.4% YoY)	(+15.6% YoY)	(-8.0% YoY)

Operating Performance#

Revenue	Adj EBITDA	Adj PAT
3,201 cr	370 cr 11.6%	193 cr 5.9%
(+4.5% YoY)	(+1.0% YoY)	(+1.6% YoY)

Segment Break-up

Business Vertical	Share in 9M FY26 revenue
CDMO	**79.1%**
Domestic Branded Formulation	**10.8%**
API	**4.5%**
International Branded Formulation	**3.4%**
Trade Generics	**2.3%**

(Adjusted EBITDA = PBT + fair value changes to financial instrument + finance cost + depreciation and amortization – other income ; Adjusted PAT = PAT + Fair value changes to financial instrument; * Including other income; #Excluding one time impact of New Labour codes)

Profit and Loss Statement

Particulars (Rs Cr)	Q3 FY26	Q3 FY25	Y-O-Y (%)	Q2 FY26	Q-O-Q (%)	9M FY26	9M FY25	Y-O-Y (%)
Revenue	1,160	1,010	14.8%	1,018	14.0%	3,201	3,063	4.5%
COGS	679	602	12.6%	593	14.5%	1,853	1,794	3.3%
GP Margin %	*41.5%*	*40.4%*		*41.8%*		*42.1%*	*41.4%*	
Employee Expenses	189	176	7.8%	189	0.1%	555	532	4.3%
Other Expenses	145	111	30.4%	141	2.5%	423	370	14.4%
Adj EBITDA[1]	147	121	21.0%	94	55.4%	370	367	1.0%
Adj EBITDA Margin %	*12.7%*	*12.0%*		*9.3%*		*11.6%*	*12.0%*	
Finance Cost	24	5	362%	23	1.9%	70	30	133%
Depreciation & Amort.	40	45	(10.9)%	38	4.7%	114	113	0.9%
Exceptional Expenses	18	(5)	-	-	-	18	(8)	-
Other Income	34	15	136%	32	6.1%	93	35	170%
Adj Profit Before Tax	100	91	9.3%	66	51.6%	261	266	(2.0)%
Tax	32	25	28.9%	23	38.8%	86	76	13.0%
Adj PAT[2]	68	66	2.1%	43	58.5%	175	190	(8.0)%
Adj PAT Margin %	*5.7%*	*6.5%*		*4.1%*		*5.3%*	*6.1%*	

(1 -Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization – other income ; 2- Adjusted PAT = PAT + Fair value changes to financial instrument)

Quarterly Performance Trends

Revenue (INR Cr.)



Adjusted EBITDA[1] (INR Cr)



Adjusted PAT[2#] (INR Cr)



(1 -Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization – other income ; 2- Adjusted PAT = PAT + Fair value changes to financial instrument - deferred tax created on brought forward losses (INR 106 cr) in Q4 FY 25; #Excluding one time impact of New Labour codes)

9M Performance Trends

Revenue (INR Cr.)



Adjusted EBITDA[1] (INR Cr)



Adjusted PAT[2#] (INR Cr)



(1 -Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization – other income ; 2- Adjusted PAT = PAT + Fair value changes to financial instrument - deferred tax created on brought forward losses (INR 106 cr) in H2 FY 25; #Excluding one time impact of New Labour codes)

Revenue and Margin Deep-Dive – Quarterly

Revenue (INR Cr.)



- Revenue growth driven by CDMO and International formulations
- In line with outlined strategy, consolidation of trade generics continues

Adj EBIDTA %



- Operating leverage led improvement in gross margins and employee expenses
- Other expenses increased due to higher power and fuel as well as professional expenses

CDMO Revenue (INR Cr.)



- Strong double digit volume growth
- Erosion in API prices responsible for negative price variance

Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization – Other income

Revenue and Margin Deep-Dive – 9M

Revenue (INR Cr.)



- 9M revenue growth driven by improved volumes in CDMO
- Erosion in API prices and consolidation in trade generics responsible for degrowth across these segments

Adj EBIDTA %



- Operating leverage led improvement in gross margins
- Other expenses increased due to higher power and fuel expenses

CDMO Revenue (INR Cr.)



- Volumes grew despite muted volumes in the IPM
- Erosion in API prices responsible for negative price variance

Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization – other income

Segmental Quarterly Performance



Segmental 9M Performance





Thank You

For further information, contact:

IR Desk

Akums Drugs and Pharmaceuticals Ltd

Email: investors@akums.net/ankit.jain@akums.net

Siddharth Rangnekar / Shruti Joshi

CDR, India

Tel: +91 97699 19966 / 75065 67349

Email: siddharth@cdr-india.com / shruti@cdr-india.com